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HIV/AIDS is one of the most encompassing and highly recognized infectious pandemics in our 
world today. It contributes significantly to total overall deaths and to economic hardship in 
societies, particularly in underdeveloped and developing countries. Access to effective 
treatments for preventing mother-to-child HIV transmission (PMTCT) during pregnancy and 
birth remain challenging, especially in resources poor settings. South Africa has one of the 
highest prevalence rates of HIV/AIDS in the world, with 5.7 million people currently infected. 
The prevalence rate of South African women of childbearing age is almost 30%, and it is 
estimated that 40,000 children are born with HIV every year. PMTCT in South Africa could be 
nearly 100% because of ARV treatments like nevirapine; however, social, behavioral, and 
governmental factors inhibit access to preventative medication and adherence to medication 
schedules. This paper used a critical review of the literature on PMTCT in South Africa, 
specifically searching for barriers associated with specific interventions. The literature review 
found barriers to the PMTCT at various levels of the Social Ecologic Model: individual, 
interpersonal, community, institutional, and policy. The Individual level barriers included 
knowledge about HIV and PMTCT, knowledge of the HIV status of mother and infant, and 
knowledge, beliefs, and fear. The Interpersonal level barriers encompassed male involvement, 
the role of traditional health practitioners, and social support. The Organization level, few 
barriers were found in the literature review of the databases, but barriers were found through the 
review of history findings from the background sections. The Community level barriers were 
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internalized AIDS stigma and infrastructure. At the Policy level, the only current barrier was 
CD4 count level for eligibility of government treatment. Adherence factors were multilevel 
barriers. The public health significance of MTCT is that 40,000 infants in South Africa are 
infected each year with HIV, a largely preventable disease, resulting in an unnecessary added 
burden to an already resource poor country. 
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1.0  INTRODUCTION 
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is one of 
the most encompassing and highly recognized infectious pandemics in our modern world today.  
Not only has it changed the face of the world in terms of total overall deaths (more than 25 
million people have died from HIV since 1981) (Joint United Nations Programme on HIV/AIDS, 
2010), but it also continues to contribute immensely to economic hardship, particularly in 
underdeveloped and developing countries.  While HIV is transmitted through sexual intercourse, 
the sharing of infected needles and blood products, and through vertical mother-to-child 
transmission (MTCT) during birth, currently no vaccinations or medications exist to eradicate 
the disease or to cure the disease after infection.  Treatment is available in the form of 
antiretroviral medications (ARVs) that help to increase patients‟ life expectancy while they are 
living with HIV/AIDS.  Some ARVs (e.g. a cocktail of nevirapine or NVP and zidovudine or 
AZT) can prevent and eliminate the transmission of HIV from mother to child during pregnancy 
and birth.  Unfortunately, access to those prenatal medicines is challenging, especially in 
resource-poor settings.  According to the Millennium Development Goals (MDG) 2010 (MDG, 
2010), over 90% of the 2.1 million children now living with HIV were infected while in the 
womb or while the mother was giving birth.  With proper treatment and access to care, almost all 
vertical infections could have been prevented.  
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South Africa, an underdeveloped country, has one of the highest prevalence rates of 
HIV/AIDS in the world.  In South Africa, 5.7 million people currently live with HIV/AIDS 
(Nicolay, 2008).  Prevalence rates among the adult population (ages 20 years to 64 years) are as 
low as 9% in the Western Cape province, while the highest rate is at 28% in Kwazulu-Natal 
province for the same population (Nicolay, 2008).  South African women between the ages of 25 
to 30 years old have a prevalence rate of almost 30%.   It estimated that 40,000 children are born 
with HIV every year, contributing significantly to the overall rate of infant mortality in South 
Africa (Statistics South Africa, 2010).  Prevention of mother-to-child transmission (PMTCT) of 
HIV in South Africa has the potential to be nearly 100% because of ARV treatments like NVP; 
however, social, behavioral, and governmental factors impact access to preventative medication 
and adherence to medication schedules. 
In South Africa, multiple factors affect access and adherence to preventative treatment 
for mother-to-child transmission.  Many of these factors can be identified using the Social 
Ecologic Model (SEM) of health as seen in Figure 1 (Glanz et al., 2008).  The SEM is an 
approach used in health behavior models for identifying different factors related to health issues.  
These different levels include: individual, interpersonal, community, institutional, and policy 
(Glanz et al., 2008).  It is important to keep in mind the various parts of the SEM in order to 
understand barriers to the PMTCT.  Previous research has shown that barriers can include HIV 
knowledge, stigma, involvement of others, and disclosure.  Having knowledge about HIV and 
PMTCT has been associated with more access and more testing (Peltzer et al., 2009; Futterman, 
Shea, Besser, Stafford, Desmond, Comulada, & Greco, 2010; and Mkwanazi et al., 2008).  
Receiving or not receiving HIV test results (Urban & Chersich, 2004; Mkwanazi, Patel, Newell, 
Rollins, Coutsoudis, Coovadia, & Bland, 2008; Peltzer & Mlambo, 2010; and Medley et al., 
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2004) and various beliefs and fear (Igumbor, Pengpid, & Obi, 2006; Kaida, Laher, Strathdee, 
Money, Janssen, Hogg, & Gray, 2010; Buskens, Jaffe, & Mkhatshwa, 2010; Peltzer et al., 2009; 
Thorsen, Sundby, & Martinson, 2008; and Varga & Brookes, 2008) can also be barriers for 
getting HIV/AIDS preventative medications and services. 
The degree of involvement and support of male partners (Auvinen, Suominen, & 
Valimaki, 2010; Visser, Neufeld, de Villiers, Makin, & Forsyth, 2008; Makin et al., 2008; 
Peltzer & Mosala, 2008; The Kesho Bora Study Group, 2010; and Peltzer et al., 2009),  Chao, & 
Dana, 2009; Peltzer & Mlambo, 2010; Peltzer, Mosala, Dana, & Fomundam, 2008; and Varga & 
Brooks, 2010) are associated with barriers in receiving and adhering to PMTCT services by 
women.  Other factors that also contribute to adherence of PMTCT include social support 
(Futterman et al., 2010; Peltzer & Mlambo, 2010; and Coutsoudis, 2005), client-counselor 
relationships (Auvinen, Suminen, and Valimaki, 2010), and disclosure of HIV status (Varga and 
Brookes, 2008; Auvinen, Suominen, and Valimaki, 2010).  HIV stigma and premarital 
pregnancy stigma (Thorsen, Sundby, & Martinson, 2008; Varga & Brookes, 2008; and Peltzer & 
Mlambo, 2010) as well as infrastrastructure (McIntyre & Bland, 2002; The Kesho Boro Study 
Group, 2010; Meyers et al., 2007; Lungiswa et al., 2007; Mate et al., 2009; and Doherty, 
Chopera, Nsibande, & Mngoma, 2009), policy (McIntyre & Bland, 2002; The Kesho Boro Study 
Group, 2010; Meyers et al., 2007; Lungiswa et al., 2007; Mate et al., 2009; and Doherty, 
Chopera, Nsibande, & Mngoma, 2009), and non-adherence factors (Mlambo, Phaswana-Mafuyo, 
& Ladzani, 2009; and Ndirangu, Newell, Tanser, Herbst, & Bland, 2010) have been shown to be 
barriers to receiving PMTCT treatment. 
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Figure 1. The Social Ecological Model (Glanz et al., 2008).  
 
The public health significance of MTCT of HIV is that 40,000 infants in South Africa are 
infected each year with HIV, a largely preventable disease, resulting in an unnecessary added 
burden to social service and health care systems in an already resource poor country.  This paper 
addresses barriers to the prevention of MTCT of HIV/AIDS in South Africa.  Specifically, it uses 
a literature search to answer the following questions: what are the barriers to PMTCT of 
HIV/AIDS? what strategies are working best to prevention MTCT of HIV/AIDS? and, what 
possible policy interventions could be implemented?  In Chapter 2, the background of the disease 
is presented through the historical context of the HIV discovery in the United States and in South 
Africa.  Chapter 3 discusses the research methods of the literature searches that were used.  In 
Chapter 4, the literature search findings of the barriers to PMTCT in South Africa are presented 
within the structure of the SEM.   The discussion in Chapter 5 describes implications for policy, 
interventions, recommendations, and research.  Chapter 6 will reflect on the conclusion and the 
article results.  
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2.0  BACKGROUND 
Opportunistic infections very similar to those associated with HIV/AIDS started to appear more 
frequently in the early 1980s.  Since then, reports have been inconclusive about the exact 
beginnings of the disease.  HIV/AIDS has spread throughout the entire world, touching every 
continent and almost every population.  More than three decades later, HIV had spread to all 
corners of the world.  In this chapter the background of the HIV/AIDS disease is discussed with 
respect to its documented beginnings in the US and in South Africa.   
2.1 HISTORY OF HIV/AIDS 
2.1.1 History of HIV 
According to an official Centers for Disease Control and Prevention (CDC) Morbidity Mortality 
Weekly Report (MMWR) (MMWR, 1981), the first reported cases of HIV/AIDS appeared in the 
United States in 1981.  The first cases were in Los Angeles, CA and were of patients who were 
homosexual men.  All had symptoms of pneumocystis carinii pneumonia (PCP).  Diagnoses 
before this point in time were considered arbitrary with respect to HIV/AIDS in terms of 
reporting, as a dearth of diagnostic information existed about the disease.  HIV was also difficult 
to diagnose because it is asymptomatic in its early stages of disease.  
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In the early 1980s, increases in Kaposi‟s sarcoma cancer, PCP, and other opportunistic 
infections were found in homosexual men in New York City and Los Angeles (MMWR, 1982).  
Under normal circumstances, these infections were found in older populations, and they were 
usually treatable when given prescriptions for two weeks.  These newly infected patients did not 
respond well to prescriptions, and they continued to seek medical treatment beyond the normal 
period for these particular infections.  In 1981, while HIV was still unnamed, it was said to infect 
people who have sexual contact with each other, specifically homosexual men (MMWR, 1982).   
Within two years HIV acquired various diagnostic names including gay-related immune 
deficiency (GRID), Kaposi‟s Sarcoma Opportunistic Infection (KSOI), community-acquired 
immune dysfunction, “gay cancer” (Altman, 1982; MMWR Weekly, 1982; and Chibbaro, 1982), 
and other names associated with symptomatic infections (e.g. lymphadenopathy and 
cytomegalovirus).  The Lancet published an opinion article in 1981 about the new infectious 
disease, calling it what many others at the time did, the “Gay Compromise Syndrome” (Brennan 
& Durack, 1981).  The New York Times reflected widespread public opinion of the time when an 
article quoted a New York City physician, Dr. Lawrence D. Mass, as stating, “gay people whose 
life style consists of anonymous sexual encounters are going to have to do some serious 
rethinking” (Altman, 1982).  In 1982, a new population of infected individuals emerged: 
injection drug users.  During the summer of 1982, the CDC reported 425 cases of this „new‟ 
opportunistic infectious disease that was emerging in the US in 23 states and in eight countries 
(CDC, 1982).  The US and the United Kingdom also sent out messages encouraging gay men to 
practice safer sex methods (The Lesbian & Gay Foundation, 2010; and Sexually Transmitted 
Infections Community Coalition of Metropolitan Washington, DC, 2010). 
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In 1982, the disease was officially named Acquired Immunodeficiency Syndrome (AIDS) 
in a meeting in Washington, D.C. (Time, 2003).  By December of 1982, 3,064 people in the US 
were diagnosed with AIDS and another 1,292 had died from it (Acquired Immunodeficiency 
Syndrome Weekly Surveillance Report (1983).  In 1982 scientists determined that HIV/AIDS 
could be transmitted through blood products, specifically blood transfusions (MMWR, 1982), as 
well as from mother-to-child during pregnancy, delivery, and breastfeeding (MMWR, 1982).  
The report confirmed that the “CDC has received reports of four infants (under two years of age) 
with unexplained cellular immunodeficiency and opportunistic infections” (MMWR, 1982).  The 
report described six other children who had opportunistic infections and had actually died from 
these infections by the time the report was released.  These were among the first published cases 
of MTCT of HIV.   
In October of 1983, world leaders gathered together for the first time to assess the global 
surveillance of HIV/AIDS in a meeting with the World Health Organization (WHO).  By the end 
of the year, the CDC confirmed that the US had 3,064 cases and 1,292 deaths and that Europe 
had 762 cases (AIDS Activity Center For Infectious Diseases - CDC, 1983).  By 1984, Robert 
Gallo, a medical doctor with the National Institutes of Health (NIH), along with the United 
States Federal Drug Administration (FDA) isolated HIV and confirmed a retrovirus as the cause 
of AIDS (FDA, 2009).  Since then, HIV has become one of the most well-known retroviruses, or 
viruses that replicate themselves and their DNA into the host cells.  Researchers traveled to 
Rwanda and other African countries in 1984, finding some of the first records of HIV/AIDS on 
the continent (Van de Perre, Rouvroy, Lepage, Bogaerts, Kestelyn, Kayihigi, Hekker, et al., 
1984).  The next year, in 1985, newly developed HIV antibody tests were created to recognize 
HIV antibodies in blood (New York University Medical Center, 2010).  The most common HIV 
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antibody test is the enzyme immunoassays (EIA).  During this year, a study by Zeigler, Cooper, 
Johnson, and Gold (1985) found that HIV could be transmitted from mother to child through 
breastfeeding.  Also in 1985, Ryan White, a 13-year-old hemophiliac, was banned from going to 
high school for being infected with HIV (Levin, Krueger, & Thorpe, 1986).  This ruling made 
Ryan White the face of discrimination in the US for being HIV-positive.  The following year 
(1986) school officials allowed him to return to school.  By the end of 1986, 85 countries 
confirmed 38,401 cases to the WHO (Bureau of Hygiene & Tropical Diseases, 1986). 
In 1987, the FDA approved the first diagnostic test for HIV/AIDS, the enzyme linked 
immunosorbant assay (ELIZA), which finds HIV antibodies in blood samples.  Because of the 
use of ELIZA and two other tests, the enzyme immunoassays (EIAs) Western Blot Test 
(Branson, 2003) and the Poly Chain Reaction (PCR) test, prevalence rates of HIV almost 
doubled from the previous year, reaching an all-time high of 71,751 cases worldwide.  In 1987 
the WHO estimated that between five and 10 million people around the world were infected with 
HIV and that 150,000 new cases would occur in the next 12 months (WHO, 1987).  
 In October 1987, HIV/AIDS became the first disease debated on the United Nations 
(UN) General Assembly floor (Mann, 1989). Earlier that year, the patent rights to the first 
antibody tests were also a topic of debate between US scientists and the Pastuer Institute (Palca, 
1987).  In December 1, 1988, the first World AIDS Day was commemorated (WHO Global 
Programme on AIDS, 1990).  The US introduced the first needle exchange sites in New York 
City and San Francisco in 1988 (American Civil Liberties Union, 2010).  By the end of the 
1980s, the drug trial ACTG019 verified that zidovudine (AZT) delayed the onset of symptoms in 
HIV-positive patients, even though the drug was too expensive for many patients to obtain at 
$7,000 each year (Kolata, 1989). 
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 In 1990 HIV/AIDS prevalence in the US was reported at 307,000 people living with 
HIV/AIDS (PLWHA), although this number appeared to be underreported (Chin, 1990).  The 
CDC estimated that one million people in the US had HIV/AIDS in 1990 (Chin, 1990).  
Worldwide, HIV/AIDS prevalence rates were between eight and 10 million.  Africa had the 
highest estimate at more than 5.5 million, followed by North America and South America, each 
with about one million people infected in each region.  At the beginning of the 1990s the 
International AIDS Society ruled that no international AIDS conferences would be held in 
countries whose governments had banned HIV-positive immigrants to their country; the US was 
included on this list (Bureau of Hygiene & Tropical Diseases, 1991).  In 1993, the CDC changed 
the definition of HIV/AIDS to include opportunistic infections and a CD4 count of less than 200 
(European Centre for the Epidemiological Monitoring of AIDS, 1993).  Scientists also found 
forms of HIV that were resistant to AZT, surprisingly occurring in people who were not 
currently taking the drug (Associated Press, 1993).   
By 1995 HIV/AIDS was the leading cause of death in the US for 25- to 44-year-olds 
(Altman, 1995).  During the 1990s, the first US White House HIV Strategy (San Francisco 
Chronicle, 1996), as well as the Joint UN Programme on AIDS (UNAIDS) were created 
(Garbus, 1996).  By 1999 scientists discovered that chimpanzees were most likely the direct 
causes of the first cases of HIV through simian immunodeficiency virus (SIV) (Mitchell, 1999).  
At the end of 1999 HIV became the fourth leading cause of death in the world (WHO World 
Health Report, 1999), encompassing 33 million people who were living with HIV/AIDS 
(Perlman, 1999).  
 In the early 2000s, US President Clinton stated that HV/AIDS had become a threat to the 
national security of many countries, specifically in countries where the disease could destroy 
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governments and create wars (United Press International, 2000; CNN, 2000).  While the disease 
became a threat to national security in other countries, the US became involved in controversies 
over loan agreements between African countries and drug companies for the use of ARV therapy 
patents.  US drug companies offered to finance small loans, to sub-Saharan African countries for 
the therapies and services (Kahn, 2000), but they rejected the loans expressing that supplying 
loans with interest rates, rather than the medications themselves, was insufficient (Swarns, 2000).  
Although this was a step backward in getting treatment to underdeveloped countries, in 2001 189 
countries signed the Declaration of Commitment to HIV/AIDS, which stated specific aims and 
goals to reduce prevalence of HIV/AIDS (United Nations, 2001).   
In 2001 the FDA approved the first rapid HIV test.  Also in this year, the United States 
Agency for International Development (USAID) introduced the Abstinence, Be Faithful, and 
Use Condoms (ABC) program into its approaches for decreasing HIV around the world, starting 
with strategies and funding policies in Uganda (Green, 2003).  Another 2001 strategy was set by 
Kofi Annan, UN Secretary General, when he called for nations to increase funding tenfold for 
HIV/AIDS in developing countries (United Nations, 2001).   
Two years later, in 2003, the WHO declared “that the failure to deliver treatment to 
nearly six million people with HIV/AIDS in developing countries was a „global public health 
emergency‟” (Fleck, 2003).  Because of this, the WHO set a new “three by five” goal, such that 
by 2005 three million PLWHA would be on ARVs.  
 As part of the Bush Administration‟s strategy against HIV/AIDS, the President‟s 
Emergency Plan For AIDS Relief (PEPFAR) was introduced with 15 billion dollars to provide 
ARV treatment to 200,000 people in 15 developing countries (Office of the U.S. Global AIDS 
Coordinator, U.S. Department of State, 2004).  In 2005, while disappointing news about the 
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inability of countries to reach the three by five goal was announced (UNAIDS/WHO, 2005), the 
G8 Summit leaders agreed to the creation of a new goal: to provide universal access to ARVs by 
2010 (Outcome Document from the 2005 World Summit, 2010).   
On a much more positive note, during the following year, in 2006, UNAIDS reported 
decreased prevalence rates in Kenya, Burkina Faso, and Haiti.  UNAIDS also reported statistics 
on its funding over the past decade, from a mere 300 million dollars in 1996 up to 8.3 billion 
dollars in 2005 (UNAIDS/WHO, 2006).  In the US, the introduction of a one-a-day pill for 
PLWHA was considered a major medical contribution (The New York Times, 2006).  Elsewhere 
in 2005 another contribution was made in the form of an NIH study acknowledging that 
circumcision greatly reduced the transmission of HIV/AIDS in Africa by 50% (NIH, 2006). 
A 2008 statement by Peter Piot, the Executive Director of UNAIDS, said that “The 2008 
Report on the global AIDS epidemic confirms that the world is, at last, making some real 
progress in its response to AIDS” (UNAIDS pg 11, 2008), the UNAIDS report stated that the 
goal of universal access to ARVs by 2010 would not be met (UNAIDS, 2008).  Although this 
goal was not met, by the end of 2008 four million people around the world were on highly active 
antiretroviral treatment (HAART); 73% of these people were in Africa, and there were 250,000 
children were on HAART, 45% more than recorded in 2007 (Granich, 2010).  Also in 2008, 
PEPFAR was renewed and increased its funding at 48 billion dollars for HIV/AIDS, Malaria, 
and Tuberculosis (TB) programs projected for the years of 2009-2013 (Office of US Global 
AIDS coordinator, 2009).  Also by that year the HIV-1 genome had been mapped (BBC News, 
2009).  In 2009 the US lifted the travel ban on PLWHA from other countries immigrating and 
traveling to the US (United Nations News Centre, 2009).  Beginning January 4, 2010, PLWHA 
would be allowed into the US for the first time since 1987 (Aidsmap, 2010).   
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Because of this historic event, the International AIDS Society (IAS) confirmed that the 
location of the 2012 International AIDS Conference would be held in Washington, DC (The 
White House, 2009).  In 2010 the WHO changed the PMTCT guidelines for PLWHA.  The 
previous guidelines said that PLWHA who had CD4 counts below 200 should be put on ARVs.  
The new guidelines said that PLWHA with a CD4 count of less than 350 were to be placed on 
ARVs.  This change came after studies showed that ARVs could decrease viral load and prevent 
transmission much more effectively. 
Testing. Over the past decade the most recently developed tests, the rapid tests, have 
become increasingly popular at testing sites.  These rapid tests have shown to have sensitivities 
and specificities similar to the EIA-Western Blot without using specialized laboratory equipment 
for drawn blood.  In order to use the rapid tests, samples of saliva are taken, and results are 
shown within minutes of collection.  These rapid tests are especially important for testing 
pregnant women who do not know their HIV status during labor (Branson, 2003).  Accurate 
testing has been especially important in calculating prevalence rates all over the world. With 
increased efficiency of testing methods, worldwide estimates show that 33 million people today 
are living with HIV/AIDS.  
2.1.2 History of HIV in South Africa 
The history of HIV/AIDS in South Africa has been a topic of debate over a long period of time. 
Controversies still exist over the precise historical facts and figures for this country.  That being 
said, the following historical perspective is presented based on findings in a literature search. 
 When the rest of the world was experiencing major surges of HIV prevalence, AIDS 
appeared in the mid 1980s on the continent of Africa.  Through the early 1980s, the disease 
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moved into populations north of the Sahara Desert (UNAIDS and WHO, 2003).  By 1985, the 
disease spread south of the desert, escalating in sub-Saharan Africa.  In 1990 HIV was among the 
leading diseases making its way through southern African countries (UNAIDS and WHO, 2003).  
Although controversies exist about historical facts and movement of the disease, some 
agree on the progression of disease and the state of disease today.  Some historians have argued 
that transmission of HIV first occurred when African hunters were killing, dressing, and eating 
chimpanzees, and the SIV mutated into HIV.  A study completed in 2005 stated that the best 
estimates of the origins of HIV came from SIV in the countries of Guinea Bissau and Cameroon 
in the early 1900s (Keele et al., 2006).  In 1987 two flight attendants who had just traveled from 
the US were clinically diagnosed with HIV/AIDS in South Africa (Ras et al., 1983).    
The first year that an AIDS conference was held in an African country was in 1995, when 
the conference of PLWHA was held in Cape Town (The Associated Press, 1995).  In 1998, as 
spread of the disease increased dramatically, the first case of HIV/AIDS related abuse occurred.  
South African activist Gugu Dlamini was beaten, and South African President Thabo Mbeki took 
a public stance against the stigmatization of HIV/AIDS (Bareng-Batho & S'Thembiso, 1998).  
The next year, President Mbeki made public statements saying that AZT was a toxic substance 
that is really harmful to a person‟s health (Wakin, 1999).  Although researchers had shown that 
AZT reduces symptoms of HIV/AIDS, this was the president‟s first spoken controversial 
message about the disease.  Also in 1999, South Africa was in a debate with US drug companies 
over prices for AZTs and other ARVs (BBC, 1999).   
During the first part of the 20th century, the South African Department of Health 
estimated that 2.65 million women (ages 15 years to 49 years) were infected with HIV, as well at 
2.09 million men (ages 15 years to 49 years) and 83,581 infants infected via MTCT (Health 
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Systems Research, Research Coordination and Epidemiology, 2001).  In 2000, President Mbeki 
publically stated that he believed HIV does not cause AIDS (Mbeki, 2000).  In April he went on 
to say that African AIDS is different from AIDS in other countries and that they should deal with 
the disease on their own (Daley, 2000).  In an uproar over this statement, 5,000 scientists came 
together by the end of the year to support and sign the Durban Declaration, named after one of 
South Africa‟s largest cities (Mail and Guardian, 2000).  The Durban Declaration was an 
agreement saying that HIV does in fact cause and lead to AIDS.  At the conference, Nkosi 
Johnson, an HIV-positive 12-year-old, spoke out against Mbeki‟s beliefs and urged President 
Mbeki to allow AZTs to be given to HIV-positive pregnant women as a means of preventing 
MTCT of HIV/AIDS (Sunday Times, 2000).   
As the controversy over drug access continued, drug prices were offset around the world 
when India and Brasil created generic forms of the expensive medications (Kumar, 2001; 
Yamey, 2001).  These new medications cost less than one dollar per day (Kumar, 2001).  Also in 
2001, South African AIDS activists took legal action against the South African Ministry of 
Health because of the government‟s refusal to distribute ARVs to prevent MTCT of HIV/AIDS 
(Sidley, 2001).  Because of pressure, the government of South Africa promised that in 2002, it 
would start providing NVP to HIV-positive mothers and give AZT, a pre-exposure prophylaxis 
(PEP), to women who were raped (Sidley, 2002).  As part of advertising and getting information 
out about HIV/AIDS in South Africa, a new HIV-positive Sesame Street character, Kami, 
created to show children what it is like to have HIV and what it is like to be in contact with a 
person who has the disease (Boyle, 2002).  
Not only did the South African government promise to give out ARVs (NVP and AZT) 
to those women in 2002, it also promised to provide free ARVs in public hospitals in 2003, but 
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started with the richest province of Gauteng (Baleta, 2003a).  In 2003 the Treatment Action 
Campaign (TAC) filed manslaughter charges against the South African Ministry of Health for its 
lack of response to the HIV/AIDS epidemic in the country (Baleta, 2003b).  During this time, the 
South African government was said to have been responsible for 600 deaths each day for failing 
to respond to the epidemic (Baleta, 2003b).  In 2005, Nelson Mandela announced that his oldest 
son died of AIDS that year (BBC News, 2005).  A 2005 report found that the published death 
certificates between the years of 2000-2001 were misreported and that the actual estimate of 
HIV-related deaths was two-thirds greater than the reported number (Groenewald, Nannan, 
Bourne, Laubscher, & Bradshaw, 2005).   
In 2006 South Africa had a rise of an extremely drug resistant form of tuberculosis 
(XDR-TB), and most if not all of the 25 cases were related to HIV (Boseley, 2006).  At the 2006 
XVI International AIDS Conference in Toronto, Stephen Lewis, Special Envoy to Africa for 
HIV/AIDS, responded to South Africa‟s attempt at responding to its HIV/AIDS epidemic by 
saying:  
 
 
 
After Nozizwe Madlala-Routledge took over as the Ministry of Health, she and the 
Deputy President, Phumzile Mlambo-Ngcuka, released new goals for HIV/AIDS epidemic: 1-) 
to reduce new infections by 50%, and 2-) to bring treatment to more than 80% of HIV infected 
patients (Reuters, 2007).  After just a few short months, the interim Minister of Health was fired, 
decreasing optimism that flowed through the country because of the new goals (The Associated 
Press, 2007).  A report published by Polydex Pharmaceuticals in 2007 found that the drug trial of 
South Africa is the unkindest cut of all. It is the only country in Africa … 
whose government is still obtuse, dilatory and negligent about rolling out 
treatment. It is the only country in Africa whose government continues to 
propound theories more worthy of a lunatic fringe than of a concerned and 
compassionate state... The government has a lot to atone for. I'm of the opinion 
that they can never achieve redemption (Lewis, 2006). 
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an AIDS vaccine might have increased the risk of South Africans being infected with the disease 
more than the placebo (Polydex Pharmaceuticals, 2007).  In 2007, Mbeki publically announced 
that he still did not believe that HIV was the cause of AIDS (Guardian Unlimited, 2007).  The 
following year, South African scientists went to court over unauthorized trials of vitamins they  
used and promoted as HIV/AIDS medications and because of the implementation and 
distribution of the vitamins to PLWHA throughout the country (Rice, 2008).  In 2008 Mbeki 
resigned as President of South Africa and Jacob Zuma took his place as President of the country.  
A Harvard University study was published emphasizing that 330,000 people lost their lives to 
HIV/AIDS between the years of 2000 and 2005 due to the failure of the South African 
government to distribute adequate ARVs (Chigwedere, Seage, Gruskin, Lee, & Essex, 2008).  In 
2010 a South Africa epidemiological team proposed that ARV treatment for HIV/AIDS could be 
used as PEP for transmission by decreasing viral load and diagnosing positive cases sooner 
(Williams, 2010).  
2.1.3 History of Prevention of Mother-to-Child Transmission of HIV/AIDS 
MTCT has among the highest rates of HIV/AIDS transmission (The Kesho Boro Study, 2010).  
The natural rate of transmission between mother to child varies between 15% to 35% depending 
on multiple factors, such as breastfeeding practices and adherence to treatment (The Kesho Boro 
Study Group, 2010) (PEPFAR, 2010).  According to DeCock et al., as cited in The Kesho Boro 
Study Group (2010) 5% of transmission occurs during pregnancy in utero, 15% during delivery, 
and 15% during breastfeeding.  
The first cases of MTCT were reported in 1983, and infants became the newest 
population to be infected (MMWR, pg 309-311, 1983).  Up until this point, HIV had infected 
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only the “4H club” populations: homosexuals, hemophiliacs, heroin addicts, and Haitians (Gallo, 
2006).  Two years later, in 1985, Zeiger et al. (1985) found that HIV was also transmitted 
through breastfeeding.  The WHO did not officially recognize this mode of transmission until 
1987 (WHO, 1987).  By mid 1990, the WHO estimated that three million women who were 
HIV-positive gave birth to three million infants, of whom 700,000 infants were infected with the 
virus (Chin, 1990).   
A 1991 study completed in Kigali, Rwanda, found that PMTCT might be more viable 
than previously thought (Van De Perre, Simonon, Msellati, Hitimana et al., 1991).  The study 
found that infants were becoming infected with HIV after birth when the mothers breastfed them.  
An article published in The Lancet that year reported a major contribution to PMTCT that was 
discovered in a large European study.  Researchers found that when HIV-positive pregnant 
women had cesarean sections (C-sections) the infection rate decreased by half (NIH News Alert, 
1998).  Another study, also from 1994, ACTG076, found that giving pregnant women AZT 
reduces MTCT by two-thirds (NIH News Release, 1996).  In 1994, the WHO reported that there 
were 1.5 million children worldwide infected with HIV (Fletcher, 1994), while the South African 
Ministry of Health reported that 850,000 people living in South Africa were infected with the 
virus and that 8% of pregnant women were infected (Pope, 1995).  This estimate said that seven 
to eight million pregnant women in South Africa were HIV-positive (Andriote, 1999).  
The FDA officially approved NVP in 1996 as a reverse transcriptase inhibitor (AIDSInfo, 
2010).  Evidence from 1997 showed that overall AIDS deaths as well as the number of infected 
infants decreased (Altman, 1996), mostly due to the introduction of and access to NVP.  Glaxo 
Wellcome, a drug company, reduced its ARV price by 75% when it was discovered that NVP 
reduces MTCT (CDC, 1998), although it was still considered too expensive for the developing 
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world (CNN, 1998).  Another study by Mandelbrot (1998) found that MTCT could be reduced to 
less than 1% with AZT during C-sections.  In 1998 the UN disseminated new recommendations 
on infant feeding practices because of some PMTCT studies.  It recommended that women 
should decide how to feed their babies, even though the recommendations seemed to push for 
formula feeding among HIV-positive mothers, while pilot studies in 11 developing countries 
pushed more for PMTCT (Altman, 1998).  
By the end of the twentieth century a myth about transmission spread throughout the Sub-
Saharan African region.  The myth was that men who were HIV-positive could cure the 
infections if they had sex with a virgin (Govender, 1999).  Reported data show that 2000 was the 
first time in history that HIV-positive women living in Africa outnumbered their male 
counterparts (Altman, 1999).  Also at the end of the century, the UK began offering HIV tests to 
all pregnant women in order to prevent MTCT (The Associated Press, 1999).  In December 2001 
the South African government agreed to provide free NVP to all HIV-positive pregnant women 
(Ashraf, 2001).  In 2002, the country started to implement distribution, adding that raped victims 
also receive free PEP (Sidley, 2002).  By the end of 2002 women accounted for 58% of the HIV 
population in Africa, and 50% of all HIV-positive cases worldwide were women (Farley, 2002).  
The Institute of Medicine (IOM) published findings in 2005 from various studies stating 
that NVP was a safe and effective treatment for MTCT (NIAID, 2005).  Even though NVP was 
proven to be very effective, an antenatal survey of clinics in South Africa found that 29.5% of 
pregnant women were HIV-positive by the end of 2004 (BBC News, 2005).  On a more 
progressive note, Botswana was able to reduce its MTCT rate to less than 4% in 2007 (The 
Boston Globe, 2007).   
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By 2009 Sub-Saharan Africa reports stated that only 45% of HIV-positive pregnant 
women were receiving ARVs (UNAIDS, 2009).  Even though researchers had discovered that 
antiretroviral treatment during and after pregnancy during breastfeeding was significantly 
associated with lower transmission rates of HIV between mother and child, there was not full 
uptake of ARVs in order to prevent MTCT of HIV. Without interventions and prophylaxis 
treatment, MTCT rate occurs at an average of 20% (The Kesho Boro Study Group, 2010).  When 
mothers are on treatment, the rates of transmission are almost nonexistent (The Kesho Bora 
Study Group, 2010).  Today WHO guidelines on prophylaxis treatment include a mixed ART 
cocktail of AZT and NVP, especially in underdeveloped countries, where these resources are 
more available (WHO, 2010).  
Breastfeeding. In developing countries, much like developing regions of South Africa, 
breastfeeding increases the rate of transmission of HIV.  In 2009 the WHO breastfeeding 
recommendations, “Guidelines on HIV and infant feeding, 2010,” were made more 
comprehensive regarding breastfeeding among women who are HIV positive and their babies 
status is either negative or unknown (WHO, 2010).  The following are some of the 
recommendations from the report: 
1- ) Integrating HIV interventions into maternal and child health services: National 
authorities should aim to integrate HIV testing, care and treatment interventions for all 
women.  
2- ) Setting national or sub-national recommendations for infant feeding in the context of 
HIV: National or sub-national health authorities should decide whether health services 
will principally counsel and support mothers known to be HIV-infected to either: 
a. Breastfeed and receive ARV interventions, or 
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b. Avoid all breastfeeding, as the strategy that will most likely give infants the greatest 
chance of HIV-free survival.  
This recommendation should be based on international recommendations and considerations of 
the: 1-) the socio-economic and cultural contexts of the populations served by maternal and child 
health services, 2-) availability and quality of health services, 3-) local epidemiology including 
HIV prevalence among pregnant women, and 4-) main causes of maternal and child under-
nutrition and infant and child mortality.  
By the end of 2000 in the US, only 200 cases of MTCT of HIV/AIDS had occurred, but 
there were over 600,000 MTCT cases of HIV/AIDS in the rest of the world (McIntyre & Gray, 
2002).  The latest data for the US show that in 2005 only 67 newborns were perinatally infected 
with HIV/AIDS (CDC- MTCT fact sheet).  Unfortunately, for developing countries like South 
Africa, various issues with access to these drugs have been a hindrance to reducing the rate.  In 
South Africa alone, the statistics show that MTCT was responsible for over 40,000 newborns 
being infected with HIV/AIDS in 2007 MTCT (Statistics South Africa, 2010).  
 In 2000, Zwi published an article in The Lancet stating that programs reducing MTCT of 
HIV in South Africa can save a minimum of 15,000 lives per year (Zwi, 2000).  Questions are 
raised about the disparities in accessing medications, especially when the disease has been 
proven to be almost completely preventable in newborns, and the government of South Africa 
has developed a national health policy to include free distribution of medications for pregnant 
women who are HIV-positive.  
Since the discovery of the HIV almost 30 years ago, some progress has been made to 
prevent the spread of the epidemic. Although prevention strategies are available, barriers exist to 
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accessing and successfully utilizing them. Prevention strategies that have proven to be effective 
include the use of antiretrovirals and nevarapine during pregnancy and the use of condoms.  
The SEM is an ecological theory model created to understand how factors at different 
levels can have an influence on health issues, specifically health behavior.  This model assumes 
that interventions, programs, and solutions that focus on a limited scope will not be fully 
effective and/or sustainable.  In order to have a wide, effective scope on health issues and for the 
interventions to be sustainable, social ecological models use a multi-level approach in 
designating barriers and facilitators at each level.  Social ecological models incorporate five 
levels: 1- Intrapersonal, 2- Interpersonal, 3- Organizational, 4- Community, and 5- Policy (see 
Figure 2).   Throughout these levels there are factors that play roles in mediating or inhibiting 
effectiveness of interventions.  These factors incorporate the physical environment and 
sociocultural issues, which influence areas in a variety of ways.  Since a full list of prevention 
strategies does not exist in a single location for the prevention of MTCT, identification of 
barriers will help to discover where they take place.  The SEM will be used to identify social 
barriers to the PMTCT in the different phases of society (Glanz et al., 2008).  Looking through 
the lens of the SEM, many of the barriers that exist for prevention are mainly social, political, 
institutional, and interpersonal barriers.   
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3.0  METHODS 
This paper is a critical review of the literature on PMTCT in South Africa, specifically the 
barriers that are associated with specific prevention interventions. In this chapter there will be a 
discussion on the methods that were used to conduct this literature review. 
Information and peer-reviewed articles were collected using the Pub Med and Psych Info 
databases at the University of Pittsburgh.  Four searches were completed.  Since the author 
wanted to identify only barriers specific to the country of South Africa searches were restricted 
to the country of South Africa.  The first search included the search terms “PMTCT” and “South 
Africa” because the author wanted to only look at the prevention of MTCT in South Africa and 
not other diseases or other countries.  This search yielded 66 results. The first 40 articles were 
the only articles that were used from this search.  After the first 40 were designated, limits were 
placed to receive only “Free Linked Text” articles.  This option was chosen because it allowed 
the author access to the articles at no cost.  A total of 29 articles were taken from this search.  
The second search used the terms “Prevention of Mother-to-Child Transmission of HIV” and 
“South Africa.”  This search yielded 312 results.  Limits were placed to include only “Full Text.” 
Fifty-seven articles were chosen from this search.  Going through search results, articles dealing 
only with South Africa were included for this literature review.  Article selection was based on 
these criteria: (a) articles published between 2000 to 2011, (b) articles that addressed barriers to 
interventions for PMTCT, (c) articles that addressed interventions for PMTCT, (d) articles that 
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analyzed and proposed interventions for PMTCT, (e) articles that were focused mostly on the 
country of South Africa, and (f) articles that were written in English.  Articles that did not meet 
these criteria were not selected for review.. 
 The third and fourth searches were completed in the Psych Info database.  The third 
search used “PMTCT” and “South Africa.”  Restrictions were placed on “links to full text” and 
English-only articles.  This search yielded 12 results.  In the fourth search the terms that were 
used include “Prevention of mother-to-child transmission HIV” and “South Africa.”  Restrictions 
were placed on “links to full text” and English-only article.  This search yielded 17 results.  
Other inclusion criteria were that it did not replicate what previous searches found and that the 
articles were specifically focused on the country of South Africa.  Under these restrictions this 
search yielded eight unique articles.   
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4.0  FINDINGS 
In this chapter, the findings from the literature review will be presented.  This literature review 
found barriers to the PMTCT at various levels of the SEM.   
At the Individual level, the barriers were found to be: 
- Knowledge about HIV and PMTCT (Peltzer et al., 2009; Futterman, Shea, Besser, 
Stafford, Desmond, Comulada, & Greco, 2010; and Mkwanazi et al., 2008),  
- Knowledge of the HIV status of mother and infant (Urban & Chersich, 2004; Mkwanazi, 
Patel, Newell, Rollins, Coutsoudis, Coovadia, & Bland, 2008; Peltzer & Mlambo, 
2010; and Medley et al., 2004), and  
- Knowledge, beliefs, and fear (Igumbor, Pengpid, & Obi, 2006; Kaida et al., 2010; 
Buskens, Jaffe, & Mkhatshwa, 2010; Peltzer et al., 2009; Thorsen, Sundby, & 
Martinson, 2008; and Varga & Brookes, 2008).   
The individual level section contained 13 articles.   
At the Interpersonal level the barriers were found to be: 
- Male involvement (Auvinen, Suominen, & Valimaki, 2010; Visser, Neufeld, de Villiers, 
Makin, & Forsyth, 2008; Makin et al., 2008; Peltzer & Mosala, 2008; The Kesho 
Bora Study Group, 2010; and Peltzer et al., 2009),  
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- The role of traditional health practitioners (THPs) (Peltzer, Phaswana-Mafuya, & Treger, 
2009; Peltzer, Chao, & Dana, 2009; Peltzer & Mlambo, 2010; Peltzer, Mosala, Dana, 
& Fomundam, 2008; and Varga & Brooks, 2010), and 
- Social support (Futterman et al., 2010; Peltzer & Mlambo, 2010; and Coutsoudis, 2005).   
The interpersonal level included 14 articles.   
At the Organization level, no barriers were found in the literature review of the databases, but 
barriers were found through the review of history findings from the background sections 
(Stinson et al., 2010; Urban & Chersich, 2004; and Sherman et al., 2004).  The organizational 
level section contained three articles.   
At the Community level barriers were found to be: 
- Internalized AIDS stigma (Thorsen, Sundby, & Martinson, 2008; Varga & Brookes, 
2008; and Peltzer & Mlambo, 2010) and 
- Infrastructure (McIntyre & Bland, 2002; The Kesho Boro Study Group, 2010; Meyers et 
al., 2007; Lungiswa et al., 2007; Mate et al., 2009; and Doherty, Chopera, Nsibande, 
& Mngoma, 2009).   
The community level included nine articles.   
At the Policy level the only current policy barrier was found to be CD4 count (Barker and 
Venter, 2007).  Other factors were adherence factors (Mlambo, Phaswana-Mafuyo, & Ladzani, 
2009; and Ndirangu, Newell, Tanser, Herbst, & Bland, 2010) and included two articles.  
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4.1 INDIVIDUAL LEVEL 
4.1.1 Knowledge about HIV and PMTCT 
South African studies have shown that when women have some knowledge about HIV and 
PMTCT is associated with better access to and acceptance of treatment outcomes.  In a study by 
Peltzer et al. (2009), most pregnant women who were interviewed had knowledge of HIV and 
PMTCT, but one-third (37.6%) incorrectly believed that their child would definitely become 
HIV-positive when they were born.  An intervention completed by Futterman, Shea, Besser, 
Stafford, Desmond, Comulada, and Greco (2010) raised knowledge of HIV through cognitive 
behavioral interventions and peer mentoring.  This knowledge was then associated with positive 
PMTCT outcomes including more follow-up visits and positive coping. 
Although education is an undisputed positive social commodity, more knowledge about 
HIV and PMTCT has been inversely associated with not getting tested for HIV (Mkwanazi et al., 
2008).  They also found that only 3.4% of their study participants wanted to receive their HIV 
test results on the same day that the rapid test was taken. In this instance, knowledge is not 
always equated with power; but the authors commented that when pregnant women know their 
HIV status, this piece of knowledge could be essential in accessing appropriate care for 
themselves, their partners, and their unborn.  
4.1.2 HIV status of mother and infant 
Even though HIV testing and knowledge about HIV status could greatly influence uptake of 
PMTCT medications, not knowing can be a barrier to PMTCT.  A study by Urban and Chersich 
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(2004) found that voluntary counseling and testing (VCT) and HIV testing are widely accepted 
by women who attend antenatal care services.   Among women who did not receive antenatal 
care, HIV testing was low.  A study by Mkwanazi, Patel, Newell, Rollins, Coutsoudis, Coovadia, 
and Bland (2008) found that women who were had more education about HIV were actually less 
likely to agree to HIV testing.  Overall, rapid testing and knowledge of results was not accepted, 
and few women wanted to receive their results the same day as testing.  
Peltzer and Mlambo (2010) investigated factors that determine whether infants are tested 
through PMTCT, hypothesizing that knowledge of an infant‟s status is vital to the survival of the 
infant.  They found that participating in a PCR test was associated with the mother‟s HIV status 
disclosure and attendance at a support group.  In this study, authors also found that mothers had 
general knowledge of PMTCT.  A Peltzer et al. (2010) study identified nine general barriers for 
mothers refusing to get an infant tested for HIV.  They include the following:  
1- Mothers were not yet ready for their child to be tested; 
2- Mothers did not know much about testing or its availability; 
3- Mothers believed that their infant was healthy, therefore not needing testing; 
4- Mothers gave reasons such as mental illness and no transportation to a testing facility; 
5- PCR testing for HIV was not available at the testing site; 
6- Mothers simply did not want their child to be tested for HIV; 
7- Mothers did not think that testing was needed because they did not perceive a risk in 
HIV transmission; 
8- Mothers were emotionally not ready to test their child; 
9- Partners of mothers would abuse them if their infant were tested for HIV. 
A report by Medley et al. (2004) described the barriers to women‟s disclosure of their 
HIV status to sexual partners.  Some of the barriers to disclosure were fear of rejection, fear of 
discrimination, fear of verbal abuse, and concerns about public ignorance of the disease.  In this 
study of South African women who did disclose their HIV status to their partner, 27% reported 
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at least one problem, 13% reported experiencing violence from partners, 9% reported that their 
partner left them, and 3% of the women were forced to move away from their home. 
4.1.3 Knowledge, beliefs, and fear 
Igumbor, Pengpid, and Obi (2006) surveyed pregnant women about their knowledge and beliefs 
surrounding PMTCT.  They found that 85% of their participants had heard about PMTCT, and 
that belief about control of the disease contributed to behavioral intent.  As the number of 
participants that were exposed more to health education information increased, so did the number 
of participants attending ANCs and receiving NVP.  
In an article by Kaida et al. (2010), the authors reported that preventing unintended 
pregnancies could reduce PMTCT.  For this to happen, their suggestion is to increase the 
numbers of HIV and reproductive health services and amount of education on those topics.  
Women receiving HAART also had a lower chance of unintended pregnancy due to the 
association between HAART adherence and increased number of women using contraceptives.  
This article emphasized that education about PMTCT services could have an impact on 
reproductive health choices.  
Mothers in South Africa know that HIV can be transmitted from mother to child through 
breast milk (Buskens, Jaffe, & Mkhatshwa, 2010; Peltzer et al., 2009; Thorsen, Sundby, & 
Martinson, 2008).  The WHO recommends that women who are HIV-positive breastfeed 
exclusively for the first six months, then if economically possibly, either switch to mixed 
methods, adding formula to breastfeeding or solely use formula (WHO, 2010).  In a study by 
Busken et al. (2010) about breastfeeding practices, mothers were found to believe that 
breastfeeding was the optimal practice rather than using formula.  Thorsen et al. (2008) also 
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found that most mothers in their study practiced breastfeeding until six months, but many 
mothers did not wean the babies after six months, as recommended to prevent future risk of HIV 
transmission.  
Further studying beliefs and fear about HIV/AIDS, Varga and Brookes (2008) examined 
adherence to PMTCT in teens, ages 15 years to 18 years.  They found that fear of a positive test 
result and concerns about confidentiality were important factors in uptake and participation in 
PMTCT services.  
4.2 INTERPERSONAL LEVEL 
Women are often times influenced by the people close to them, particularly people in their close 
social groups (e.g. male partners), or by others who have high influence on them (e.g. traditional 
birth attendants).  The role that others play in the pregnancy process affects pregnant women on 
an interpersonal level and can serve as barriers to prevention at that level.  In South Africa the 
role of others in a woman‟s life often plays another role in being a barrier to PMTCT of HIV.  
4.2.1 Male involvement 
Auvinen, Suominen, and Valimaki (2010) investigated how male partners‟ participation in 
pregnancy influences the pregnancy process and the prevention of HIV from mother-to-child 
transmission in Africa.  The authors describe male partners as either supportive or non-
supportive.  Supportive males are willing to be tested for HIV and to communicate with their 
partner about reproductive issues, which help to increase the commitment of pregnant women to 
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PMTCT programs.  Non-supportive males do not engage in open discussion with their partners. 
Having non-supportive male partners often times is associated with HIV-related intimate partner 
violence (IPV), abandonment or fear of abandonment.  In another study, Visser, Neufeld, de 
Villiers, Makin, and Forsyth (2008) found that recently diagnosed HIV-positive women feared 
abandonment, discrimination, blame/anger, and violence upon disclosing information to their 
partners.  When women did disclose their HIV status to their partner, the partners mostly reacted 
with disbelief and shock as forms of participation.  Makin et al. (2008) found that being able to 
disclose HIV status was associated with previously discussing testing, being married, having a 
partner with higher education, and having experienced less violence.  
Another study by Peltzer and Mosala (2008) found that while only 14.9% of male 
partners of pregnant women attended an antenatal clinic (ANC) visit, those women were 
significantly more likely to be tested for HIV and receive their results.  This study also found that 
maternal uptake of NVP before birth was associated with telling their male partner about the 
medication treatment.  
In a randomized control trial by The Kesho Bora Study Group (2010) about differences in 
types of antenatal HIV medication, clinicians encouraged women to talk with a partner or friend 
who supported their decision to adhere to the medication.  They hypothesized that if the women 
had social support, they would adhere to the medication better.  Peltzer et al. (2009) also 
recognized the importance of partner support.  They discovered that when women told their 
partner about their decision to take NVP, adherence to the medication increased. 
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4.2.2 Health practitioners 
Traditional health practitioners (THPs), such as herbalists, diviners, and birth attendants (TBAs), 
have strong influence on acceptance of and adherence to PMTCT for mothers.  Peltzer, 
Phaswana-Mafuya, and Treger (2009) found that THPs and TBAs were frequently contacted 
during pregnancy to check a baby‟s position, rub the stomach (for wind), check the baby, and get 
medicine (for wind). Post-natally, THPs and TBAs were contacted for physical check-ups, infant 
feeding advice, referral to a health facility, baby baths and cleaning the cord, advice on nutrition 
of the mother, family planning, and medicines for various ailments of mother and infant.  Almost 
half (45.9%) of the mothers in the study did not contact a THP or TBA, while 34% used their 
services in postnatal care (Peltzer et al., 2009).  
Other studies have found that social support influences PMTCT.  Peltzer, Chao, and Dana 
(2009) found that male involvement (e.g. going with the women to the antenatal care, 
discussions about preventing pregnancy with condoms, and discussions about preventing STIs 
with condoms) was significantly positively associated with mothers getting an HIV test and 
knowing their HIV status.  In this study, only 14.9% of HIV-positive women‟s partners and 
15.3% of HIV-negative women‟s partners accompanied them to the antenatal clinic.  A study by 
Peltzer and Mlambo (2010) found that having a support group of mothers significantly 
influenced HIV-positive mothers to participate in HIV testing of themselves and their infants.  
Similarly, women who had a partner accompany them to a clinic were significantly more likely 
to get tested for HIV (Peltzer, Mosala, Dana, & Fomundam, 2008).  Client-counselor dynamics 
during a pre-test counseling session were also extremely important in the maternal uptake of 
PMTCT among teen mothers ages 15- to 19-year-olds (Varga & Brooks, 2010).  
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4.2.3 Social support 
Other means of social support were regarded as factors influencing adherence to PMTCT.  In an 
intervention by Futterman et al. (2010) mothers were placed in a support group intervention with 
other mothers in similar situations, and they received services provided by midwives and 
counselors.  Women who were part of the Mother2Mother Mamekhaya CBI intervention were 
more likely to improve their well-being and their adherence to follow-up appointments. Peltzer 
and Mlambo (2010)‟s findings supported the importance of social support groups, such that a 
mother getting her infant tested was associated with being in a support group, as well as being 
older, experiencing less depression, having fewer PMTCT risk behaviors and higher PMTCT 
knowledge, and disclosing HIV status.  Coutsoudis (2005) also found that social support was 
imperative for adherence to PMTCT programs.  In her article about breastfeeding, she found that 
women who had better social support were able to wean earlier than they originally intended to, 
a practice advised by the Safer Breastfeeding Programme to reduce available time for MTCT to 
occur.  
4.3 ORGANIZATIONAL LEVEL 
Stinson et al. (2010) looked at organizational barriers to the PMTCT.  They found that there was 
a failure of organizations to prioritize eligible HIV-positive pregnant women and to initiate 
HAART to those eligible in government-sponsored treatment regimens.  They found that only 
51% of eligible pregnant women actually started HAART before delivery, and 22% did not 
receive any PMTCT intervention before delivery.  
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Urban and Chersich (2004) found that organizations such as hospitals have more capacity 
for VCT and HIV testing among their patients for PMTCT purposes than in other regions where 
hospitals are not available.  Some of these rural areas included facilities and programs where 
staff was inadequate and health system infrastructure capacity in the area was also inadequate.  
In areas where pregnant women did not receive antenatal services, HIV testing was low. 
An institution‟s organization and clarity of records have also been barriers to 
understanding effectiveness of PMTCT programs.  Sherman et al. (2004) cited that better 
facilities, better record-keeping and continual monitoring them would inevitably help to reduce 
MTCT of HIV.   
4.4 COMMUNITY LEVEL 
4.4.1 Internalized AIDS stigma 
HIV/AIDS stigmatization has historically had an influence on many societal issues in South 
Africa.  PLWHA are vulnerable to verbal, physical, and emotional abuse from others who have 
negative feelings toward HIV. Such negativities around pregnancy and HIV (e.g. promiscuity, 
infidelity, prostitution) have an influence even on PMTCT (Thorsen, Sundby, & Martinson, 
2008).  
A study by Thorsen et al. (2008) has shown that AIDS stigma is associated with less 
disclosure of HIV status of women and their partners.  This means that women do not disclose 
their status to others because of HIV/AIDS stigma associated with the disease.  Women do not 
want their partners to perceive them as a prostitute or label them as an adulterer.  Women fear 
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abandonment, abuse, and banishment from their family and community.  There are times when 
HIV-positive mothers will not disclose their HIV status but show signs of the disease through 
other behaviors. Mothers will not take medications, resulting in flu-like symptoms, being 
chronically ill, and eventually leading to wasting.  They will visit the clinic for PMTCT more 
frequently, wean their infant quicker than normal (i.e. after six months, as recommended by the 
WHO (2010), and will bottle-feed more often.  
In a study by Varga and Brookes (2008), teen participants were less likely to have 
positive PMTCT outcomes because of the influence of HIV stigma. Adolescent mothers were 
given questionnaires asking about their participation in PMTCT services. They mentioned that 
often they were concerned about premarital pregnancy stigma and HIV-related stigmas. The 
teens were apprehensive about confidentiality of their status and poor treatment from health care 
providers. They also mentioned elaborate means of keeping their HIV status concealed from 
labor and delivery staff, even though they knew they would be omitted from tailored, necessary 
treatment.  Also, in examining factors that determine HIV testing of infants, Peltzer and Mlambo 
(2010) found that internalized AIDS stigma did influence testing. Women who reported feeling 
the stigma of AIDS, measured by reflecting on self-abasement and negative self-perceptions 
relating to a person living with HIV, were tested and had their infants tested less often or not at 
all, than those who did not feel influence from stigma. 
4.4.2 Infrastructure 
Infrastructure of communities and health care facilities in those communities can enhance or 
curtail the implementation of PMTCT interventions.  As McIntyre and Bland (2002) put it, “few 
places have antenatal care services sufficiently well established to introduce voluntary 
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counseling and testing without some additional resources.”  They also went on to say that 
changing the infrastructure to provide counseling and testing will take many years and that if the 
government implements universal administration of PMTCT programs, it may compound 
problems with adherence.  
During the randomized control trial of The Kesho Boro Study Group (2010), problems 
with infrastructure were identified.  Even though the study was looking at differences between 
continuous triple-ARV combination therapy and single dose NVP (sdNVP), the report found 
challenges to PMTCT in the infrastructure of hospitals and clinics.  The article noted that the 
high turnover of staff in the government and in the clinics was a hindrance to PMTCT as well as 
the paperwork that went into the study because of the amount of time and larger logistical 
problems.  
The lack of sufficient healthcare staff and facilities was also a barrier to successful 
PMTCT programs in a Meyers et al. (2007) study as well as in a Lungiswa et al. (2007) study.  A 
major problem from healthcare facilities in South Africa has been the lack of complete and 
accurate data collection (Mate et al., 2009). Another study by Doherty, Chopera, Nsibande, and 
Mngoma (2009) looked at strengths and weaknesses of the healthcare system.  They found that 
the system had weaknesses in training and supervision.  Doherty and colleagues also found that 
in order to increase treatment and testing among pregnant women, health facilities need use data-
driven reports to prioritize their PMTCT programs and interventions.  Lungiswa et al. (2007) 
acknowledged that a lack of counselors and testing equipment was a barrier in utilizing PMTCT 
interventions.  They also noted that failures of the health system, including lack of HIV testing, 
lack of VCT, and lack of mothers receiving their test results contribute to health system barriers 
to PMTCT.  
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4.5 POLICY LEVEL 
South Africa has had a difficult time getting over the stigma of HIV/AIDS with respect to the 
policy issues from influential political characters.  People who have been in high governmental 
positions have influenced the way some South Africans view the disease.  Reflecting on 
historical events that occurred in South Africa, the former president, Thabo Mbeki, provided 
public statements falsely believing that HIV was not the cause of AIDS and that AZT is a toxic 
substance that is harmful to a person‟s health.  Other public figures have also been in the 
spotlight for their opinions and events with HIV/AIDS.  Nelson Mandela, for example, admitted 
publically that his son had died of HIV/AIDS, which helped him to become an advocate against 
the disease in proactive ways. 
 Other issues in policy have stimulated or inhibited the progression of HIV/AIDS in South 
Africa.  In 2010 the South African Department of Health introduced new PMTCT protocol 
changes to the healthcare system.  With guidelines from the WHO, these two new policy changes 
were as follows:  
1- Pregnant women with a CD4 cell count of more than 350 cells/ mm3 and WHO stage 1 
and 2 disease should receive antiretroviral prophylaxis with AZT to reduce mother-to-
child transmission. 
2- Pregnant women with a CD4 cell count of 350 cells/ mm3 or less WHO clinical stage 3 or 
4 should receive lifelong antiretroviral treatment, both for their own health and to reduce 
the likelihood of mother-to-child transmission.  
In the South African Medical Journal, Barker and Venter (2007) emphasize the importance of 
the South African government to increase PMTCT by increasing HAART to pregnant women in 
order to decrease the MTCT rate of HIV as well as reducing the number of children needing 
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HAART.  As more than 600,000 people are HAART eligible and fewer than 100,000 are 
receiving treatment, PMTCT would help to reduce the overall treatment gap.  Even though the 
South African government increased the number of women eligible for ARVs during pregnancy, 
access and eligibility are barriers to receiving effective preventive care (South Africa Department 
of Health, 2010).  
4.6 OTHER: ADHERENCE FACTORS 
Adherence to PMTCT services (e.g. adherence to NVP for mother and child, attending follow-up 
appointments, medication uptake, and to HIV testing) is determined by multiple factors.   
Peltzer published an article with Mlambo, Phaswana-Mafuyo, and Ladzani (2009) in 
which they found that factors affecting adherence to NVP included PMTCT knowledge, more 
than two ANC visits, consultation with a TBA during pregnancy, quality of post-test HIV 
counseling, disclosure of HIV test result, discussion with partner about NVP, victimization 
because of HIV status, confidentiality protocols regarding HIV status at health facility, health 
facility delivery, term delivery, infant HIV status, and maternal NVP adherence.  Another 
investigation by Ndirangu, Newell, Tanser, Herbst, and Bland (2010) found that children who 
are born at home have a 35% higher risk of dying than children who were born in a clinic with 
single-dose NVP available.  The availability of PMTCT and ARVs in public health programs 
could have explained 8% to 31% of the decline in the mortality rate of children under the age of 
two years from 2000 to 2005. 
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5.0  DISCUSSION 
This chapter will focus on a discussion based on the findings of the literature review.  
This review of literature looked at finding research that was published recently in 
addressing barriers that affect the prevention strategies of MTCT of HIV/AIDS.  In doing this 
literature review, some of the relevant research articles might not have been included because 
they were most likely not found in the databases or they were costly.  The databases that were 
included were chosen specifically for their variety and quality of articles to help address this 
PMTCT issue in South Africa.  Some of the articles that were found in the searches addressed 
PMTCT issues of Sub-Saharan Africa or other African countries, but these articles were not 
included because the issues in South Africa are unique to the history of HIV in the area, to the 
country itself, and to the people who live in the country.  The limitations that were placed on 
article selection were strategic in that they were to only cater to those in South Africa and to 
those that were readily accessible through the University of Pittsburgh‟s open databases.  
Barriers to PMTCT not only have various cultural implications in South Africa because of the 
heterogeneous population, but also throughout the entire continent of Africa.  As the articles that 
looked at different countries could have been particularly relevant to this literature review for 
South Africa, they were still not included because they were irrelevant with regard to the actual 
people who are to be receiving services in the country.  
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5.1 IMPLICATIONS FOR POLICY 
Within the past year, new policies have been put in place to help further reduce the MTCT of 
HIV in South Africa.  The newest policy in South Africa has allowed for more PLWHA to be 
eligible for free ARVs through governmental programs.  This policy states that for PLWHA and 
who have less than a 350 CD4 count, they can receive free ARVs from the government of South 
Africa.  The other policy is a recommendation from the WHO and it addresses the issue of 
breastfeeding practices for underdeveloped and developing countries.  In places where an 
adequate clean water supply is not available, the WHO recommends that mothers who are HIV 
positive, should continue to breastfeed their infant for at least six months in order to receive the 
immunity benefits that help prevent other widely spread infectious diseases that are 
commonplace in developing nations.  
Through this literature review other issues for policy implications have been identified.  
HIV positive pregnant women who are unable to travel to the hospital in time for labor, may 
miss the opportunity to take sdNVP, HAART, or other PEP for PMTCT of HIV.  It is 
recommended that women who are HIV positive be given sdNVP or HAART to take with them 
when they make a visit to an ANC or health clinic for prenatal care.  This will ensure that they 
have the preventative medication readily available by the time of delivery, no matter where they 
are located.  
It was also found that policies regarding THPs and TBAs should be implemented. It is 
recommended that THPs and TBAs be trained comprehensively in regard to understanding HIV 
transmission and PMTCT.  The recommendation is that these professionals be trained about high 
HIV risk practices, optimizing their services, HIV prevention, infant feeding, and family 
planning.  Although this specific recommendation is culturally sensitive to the people and 
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practitioners who are in the location using the services, it is recommended that THPs and TBAs 
receive adequate, full coverage of the topic so that they will have comprehensive, effective 
knowledge on the HIV and how to prevent MTCT.  
5.2 IMPLICATIONS FOR INTERVENTIONS 
This literature review found and analyzed some interventions that have already been implicated 
in South Africa regarding PMTCT of HIV/AIDS.  Some of the positive, effective programs have 
been the Mothers2Mothers program dealing with social support, a program that acknowledges 
the need for more testing, and the Keso Bora study providing information on safe breastfeeding.  
Some key priorities for interventions include: male involvement, social support, more testing, 
continuous training for medical personnel, voluntary counseling and testing, and attendance at 
ANCs.  Interventions should focus on increasing testing of mothers and infants as well as 
mothers getting testing results back.  When mothers know that they are HIV positive or that their 
infant is HIV positive, they can prevent further degradation of health by receiving ARV 
medications and knowledge about preventing further transmission.  Interventions should also 
increase social support of HIV positive pregnant mothers with male/partner involvement in the 
pregnancy and with other mothers who are going through the same issues.  Social support is 
incredibly important to the adherence of healthy practices and the prevention of transmission 
from mother to child during birth.  
Other interventions could include continuous HIV training for health care staff, a push for 
ANC visits, and a renewal of the infrastructure of health care facilities.  Since South Africa has 
the highest prevalence rate of PLWHA, health care staff at all levels, medical doctors to TBAs, 
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should be well versed in safe practices and preventative strategies in addressing HIV/AIDS in 
every situation.  Although changing the atmosphere and infrastructure of the health care facilities 
and the health care system could be more difficult to address, it is important to mention them and 
consider them in all interventions.  Health care facilities need to be better equipped to handle 
PLWHA and their medical issues while dealing with the disease.  For pregnant women in South 
Africa, this means having an adequate supply of medications that prevent MTCT of HIV/AIDS 
and having adequate staff members to provide voluntary counseling and testing.   
5.3 IMPLICATIONS FOR FUTURE RESEARCH 
It would be very beneficial for singular studies to address all of the barriers of PMTCT, but the 
question of feasibility and efficacy remains an obstacle.  Looking through the research, some of 
the articles addressed single or multiple barriers, but none addressed all of the barriers that were 
identified in the literature review.  Future research could use the SEM as a starting point to 
formulate research at different levels of society.  This would be beneficial for structuring where 
there are gaps in research and where there are bigger gaps at different levels.  Future research 
would also benefit from receiving input from community members in various villages across the 
country to see whether or not there are differences between different areas of South Africa itself 
as a country.  
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5.4 LIMITATIONS 
Since this analysis was a literature review, no new data was generated and the author was only 
able to read articles that were published in English.   
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6.0  CONCLUSION 
In this chapter the conclusion will focus on the main parts of the historical perspective with 
emphasis on the important findings from the literature review. 
The extremely high number of HIV positive South Africans has been an individual, 
interpersonal, community, institutional, and national issue for more than three decades.  
Decreasing the global burden of disease is possible through public health initiatives and 
interventions to prevent transmission.  One of the most effective ways to prevent transmission is 
to focus on preventing MTCT, which accounts for an estimated 40,000 HIV-infected infants 
each year.  With proper medication MTCT could be significantly eliminated in South Africa.  
Although HAART and NVP can reduce transmission to less than 1%, mothers have not been 
able to obtain treatments like these for various reasons.  Barriers to getting treatments have been 
outlined in this thesis and include: intrapersonal (knowledge about HIV and PMTCT, knowledge 
about HIV status, fear and beliefs), interpersonal (involvement of males, THPs, and social 
support), organizational (capacity for staff, clear record keeping, and organization), community 
(stigma, beliefs, and infrastructure), and policy (eligibility in receiving treatment).  If these 
barriers were decreased or eliminated, children would not have to live and suffer with HIV/AIDS 
from birth, major HIV-related national security issues could be averted, and South Africa could 
decrease its national burden of HIV/AIDS.  
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  APPENDIX  
LITERATURE FINDINGS AND HISTORICAL TIMELINE 
TABLE 1: The Social Ecological Model of Barriers to the Prevention of Mother-to-Child 
Transmission of HIV/AIDS 
Individual Level Barriers 
 Knowledge about HIV and PMTCT 
 HIV status of mother and infant 
 Knowledge, beliefs, and fear 
Interpersonal Level Barriers 
 Male involvement 
 Health practitioners 
 Social support 
Organizational Level Barriers 
Community Level Barriers 
 Internalized AIDS stigma 
 Infrastructure 
Policy Level Barriers 
Other Barriers: Adherence Factors 
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TABLE 2: Table of Literature Review Results
Literature Search 1: PubMed 
Search Terms:  
     “PMTCT” 
     “South Africa” 
Results: 
     66 articles 
 
Literature Search 2: PubMed 
Search Terms:  
     “Prevention of Mother-to-Child Transmission” 
     “South Africa” 
Results: 
     312 articles 
 
Literature Search 3: PsychInfo 
Search Terms:  
     “PMTCT” 
     “South Africa” 
Results: 
     12 articles 
 
Literature Search 4: PsychInfo 
Search Terms:  
     “Prevention of Mother-to-Child Transmission” 
     “South Africa” 
Results: 
     17 articles 
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TABLE 3: Comparison of Articles: Showing Barriers to the Prevention of Mother-to-Child 
Transmission of HIV/AIDS in South Africa 
Author (Year) Aim Study Sample Methods Results: Barriers 
Auvinen et al.  
(2010) 
To summarize how 
male participation 
in HIV programs 
has been studied 
and to describe how 
male participation 
is identified and 
described in 
different studies 
31 studies (29 
articles and 2 
abstracts) 
Qualitative look 
at multiple 
articles 
identifying  
Articles identified 
supportive males and 
non-supportive 
males. Supportive 
males increase 
pregnant women‟s 
commitment to 
PMTCT. Non-
supportive males 
associated with 
intimacy violence, 
abandonment, fear, 
and lack discussion 
Coutsoudis  
(2005) 
To better 
understand how 
women respond to 
the Safer 
Breastfeeding 
Programme for 
HIV-positive 
women 
315 mothers 
enrolled in the 
MTCT 
prevention 
program 
Operational 
study design to 
understand the 
influence of 
promoting safer 
breast-feeding on 
feeding 
behaviors and 
HIV 
transmission in 
this program 
Difficulty to stop 
breast-feeding earlier 
than the norm; 
breastfeeding 
knowledge and HIV 
transmission 
Kaida et al.  
(2010) 
To investigate 
whether the 
prevalence of 
contraceptive use 
and method 
preferences vary by 
HIV status and 
receipt of HAART 
among women in 
Soweto, South 
Africa 
563 non-
pregnant 
women, 171 
were HIV-
positive and 
on HAART, 
178 HIV-
positive and 
HAART 
naive, 214 
HIV-negative 
Cross-sectional 
survey data of 
HIV-positive and 
HIV-negative 
women receiving 
services at a 
prenatal unit. 
Logistic 
regression 
models estimated 
adjusted 
associations. 
ANOVA and 
Pearson‟s Chi-
HIV-status; 
adherence to 
HAART  
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squared were 
used to 
determine 
significant 
differences and 
associations 
Kesho Bora 
Study Group  
(2010) 
To evaluate 
strategies to reduce 
HIV-1 transmission 
through 
breastfeeding and 
to optimize use of 
ARVs during 
preganancy 
1140 HIV-
positive 
women 
Random control 
trial  
Adherence to 
medication; financial 
constraints; time of 
ARV initiation; 
quality and 
commitment of 
health care workers; 
paperwork; stigma 
McIntyre et al.  
(2001) 
To examine 
whether the success 
of PMTCT 
treatment, and 
infant feeding 
practices, can be 
repeated in poor 
countries 
Medline 
article search 
used 24 
resources 
Medline search 
for original 
articles 
Adherence; 
breastfeeding; 
implementation of 
program 
progression; cost; 
infrastructure 
Medley et al.  
(2004) 
Review of available 
information on HIV 
status disclosure 
among women in 
developing 
countries, 
specifically  
synthesizing the 
rates, barriers, and 
outcomes of HIV-
positive women 
Journal 
articles and 
abstracts from 
January 1990 
to December 
2001, from 4 
major 
databases 
Synthesis and 
analysis of 17 
peer-reviewed 
journal articles 
and international 
conference 
abstracts 
Fear of rejection, 
discrimination, and 
verbal abuse; 
concerns about 
public ignorance of 
disease 
Mkwanazi et 
al.  
(2008) 
To report on the 
acceptability of 
HIV counseling and 
testing, and uptake 
of results, before 
and after the 
introduction of 
rapid testing in 
rural South Africa 
12,323 
pregnant 
women 
receiving 
counseling 
and testing at 
8 antenatal 
clinics 
Pregnant women 
were offered 
HIV voluntary 
counseling and 
testing before 
enrollment in a 
cohort study 
investigating 
infant feeding 
and HIV 
transmission 
HIV test; 
acceptability of test 
result; knowledge of 
HIV status 
Ndirangu et 
al.  
To investigate 
temporal and 
Birth records 
from January 
A retrospective 
cohort analysis, 
Availability of 
PMTCT and ART; 
Table 3 continued 
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(2010) spatial associations 
of infant mortality 
in high HIV-
prevalent areas with 
a PMTCT program, 
an HIV treatment 
program, and 
maternal HIV 
2000 to 
January 2007 
in rural South 
Africa (the 
Umkhanyaku
de district of 
KwaZulu-
Natal) 
using various 
statistical 
methods  
maternal education; 
birth location 
Peltzer et al.  
(2010) 
To investigate 
factors determining 
HIV viral testing of 
infants in PMTCT 
context 
311 women 
and mothers 
(18+ years 
old), infants 
(3-6 months), 
28 PMTCT 
sites 
Cross-sectional, 
private 
interviews, 12 
interviews 
completed at 
each site 
HIV testing of 
mother and infant; 
testing knowledge; 
perceived need to 
test; availability of 
test; desire to be 
tested; HIV 
disclosure; support 
group; risk 
behaviors; age; fear; 
partner support 
Peltzer et al.  
(2010) 
To identify factors 
that influence 
adherence to ARV 
prophylaxis by 
HIV+ mothers in 
PMTCT programs 
815 HIV+ 
mothers (18+ 
years old), 
infants (3-6 
months), 47 
clinics 
Interview with 
questionnaires 
PMTCT and HIV 
transmission 
knowledge; 
availability of ANC 
services, and testing 
and counseling 
services; male 
involvement; ARV 
availability; HIV 
status of mother and 
infant; ANC visits 
Peltzer et al.  
(2008) 
To investigate 
implementation of a 
PMTCT program 
and to evaluate the 
uptake and 
adherence of 
sdNVP 
758 mothers 
who received 
their test 
results, at 5 
sites, 
resource-poor 
setting 
Interviews with 
women at the 
sites. Statistical 
analysis included 
Chi-square, 
student t-test, 
logistic 
regression, and 
unadjusted odds 
HIV status; HIV 
knowledge; test 
result; male 
involvement; safe 
delivery; infant 
feeding; ART; HIV 
status of infant and 
mother 
Peltzer et al.  
(2009) 
Part of a baseline 
assessment in 
PMTCT in 
traditional health 
sector: 
To determine views 
of a women who‟ve 
181 prenatal 
clients with 
infants (less 
than 2 
months), from 
20 primary 
care clinics, 
Interview 
Questionnaires 
Attitude about taking 
medications; home 
delivery; HIV/AIDS 
knowledge; infection 
control; 
herbalists/diviners 
Table 3 continued 
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used THP services 
(before, during, and 
after pregnancy), 
To conduct 
formative research 
with THPs 
54 TBAs, 47 
herbalists/divi
ners 
Reynolds et 
al.  
(2008) 
To estimate the 
number of HIV+ 
births prevented by 
contraception use 
and find 
cost/savings 
benefits 
Public data 
was taken 
from 15 
PEPFAR 
countries 
Main sources of 
data were 
collected from 
the Demographic 
and Health 
Survey, Joint 
United Nations 
Programme on 
HIV/AIDS, and 
the United States 
Census Bureau 
International 
Data Base 
Contraceptive use; 
ARV availability 
and adherence 
Sherman et al. 
(2004) 
To assess the 
efficacy of a 
PMTCT program in 
a routine service 
setting in 
comparison to a 
research 
environment 
Descriptive 
data on 
PMTCT 
service from 
labor ward, 
postnatal 
ward and 
paediatric 
PMTCT 
follow-up 
clinic records 
for 13 months 
(October 2001 
to October 
2002). 297 
HIV-positive 
women 
enrolled for 
the infant 
diagnostic 
study 
Descriptive 
study during a 
13-month period 
using 
retrospective 
data from 
hospital records, 
in addition to 
prospective data 
on a sample of 
patients enrolled 
in a study 
Adherence to ARVs; 
availability of 
breastfeeding 
alternatives; follow-
up appointments; 
record keeping 
Stinson et al.  
(2010) 
To investigate 
HAART among 
pregnant women 
and to invest ideal 
model of service 
delivery for 
13,208 
pregnant 
women tested 
for HIV, 26% 
HIV+, 15% 
HAART 
Retrospective 
record analysis 
identifying 
women who 
were HAART-
eligible. 
Initiation of 
HAART; adherence 
to PMTCT services 
and interventions; 
receiving services 
before delivery; 
Table 3 continued 
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integrating HAART 
to ANCs 
eligible. 4 
ANC clinics 
Statistical 
analysis included 
proportions, 
bivariate 
analysis, Chi-
square, one-way 
ANOVA, and 
multiple logistic 
regression 
gestational age; 
prioritization of 
PMTCT 
interventions 
Urban et al. 
(2004) 
To assess the effect 
of regular audit and 
targeted 
interventions on the 
utilization of the 
PMTCT program at 
Coronation Women 
and Children‟s 
Hospital 
965 records 
were assessed 
across three 
audits 
Audits were 
conducted in 
October 2000, 
April 2001, and 
February 2002 
compromising a 
retrospective 
review of 
hospital records 
and ANC cards 
Initiation of prenatal 
care; HIV testing; 
availability and 
receipt of NVP; 
adherence to NVP 
Varga et al. 
(2008) 
To examine barriers 
to HIV testing 
uptake and 
participation in 
PMTCT services in 
adolescents 
Adolescent 
mothers (ages 
15 to 19 years 
old) in the 
rural and 
urban parts of 
the Limpopo 
Province 
Focus groups, 
workshops, pre- 
and post-test 
counseling 
Client-counselor 
dynamics; counselor 
profile; adherence to 
treatment and 
counseling; stigma; 
fear; treatment by 
health care provider; 
disclosure 
 
Table 3 continued 
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TABLE 4: Timeline of HIV/AIDS 
Timeline of HIV 
Before 
1980 
There is not much evidence of HIV statistics before 1980. 
1981 - Las Angeles and New York City see increases of PCP and Kaposi‟s Sarcoma 
- These rates are found among injection drug users, gay men, and increases were also 
found in the United Kingdom 
1982 - Names for the new disease include: Gay Cancer Syndrome, GRID, Gay Cancer, and 
AIDS 
- First AIDS organization was founded: the Terry Higgins Trust 
- More European countries started reporting new cases 
- Uganda defined the fatal, wasting disease as “slim” 
- First cases of MTCT were reported 
1983 - Reports were finding that cases were included in 4 areas: homosexuals, hemophiliacs, 
heroin addicts, and Haitians 
- These four areas were known as the 4H club 
- LAV was first isolated 
- MTCT became more prevalent 
- Global surveillance of the disease began 
- There were 3,064 US cases and 1,292 deaths 
1984 - Dr. Gallo isolated HIV as the cause of AIDS 
- Researchers traveled to central Africa and found AIDS cases 
- There were 7,699 US cases, 3,665 deaths, and 762 cases in Europe 
1985 - Tests were created to find antibodies of HIV, which no HIV-positive people were able 
to donate blood later 
- Ryan White was banned from school for being HIV-positive 
- UK started testing their blood supply 
- Bangui definition changed definition of HIV 
- MTCT was found to be transmissible through breastfeeding 
- There were 20,303 cases reported to the WHO, 15,948 in the US and 275 in the UK 
1986 - The first needle exchange was established in the UK 
- HIV became the official name of the disease 
- AZT was shown to attack HIV 
- Speculation and reports of the first African people to get HIV symptoms occurred in 
the 1970s 
- WHO estimated that 85 countries had cases, that there were 38,401 confirmed cases, 
31,741 of which were in the US and 2,323 were in Africa 
1987 - FDA approved AZT for AIDS treatment 
- Advertisements became more prevalent, such as the “1 in 61 babies born positive in 
NYC” poster campaign in NYC 
- The Pasteur Institute ended arguments with the US Department of Health and Human 
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Services over the first HIV antibody test patent 
-WHO confirms HIV MTCT through breastfeeding, but says that women should still 
breastfeed because of the benefits of it 
- In October, AIDS became the first disease to be debated on the UN floor of the 
General Assembly 
- The WHO reported 71,751 cases, where the US had the greatest number reported at 
47,022 cases and Uganda had 2,369 cases, Brazil had 2,102, and France had 2,523 
- The WHO estimated that 5-10 million people were infected worldwide, with 150,000 
new cases happening in the developing countries in next 12 months and up to 3 million 
new cases in the next 5 years 
1988 - Delegates from 148 countries meet to focus on AIDS programmes 
- First World AIDS Day was December 1, 1988 
- “Understanding AIDS” pamphlet was created, with 107 million copies in print, where 
87 million reported to have read it 
- The first needle exchanges were set up in the US in NYC and San Francisco 
1989 - Drug trial ACTC091confirmed that AZT delayed the onset of HIV symptoms in HIV-
positive patients. While a one year supply would cost each patient over $7,000, it 
would prove to be too expensive for most patients 
- Another drug was available (ddl- dideoxyinosine) 
- By March 145 countries reported 142,000 cases to the WHO where actual estimates 
should have been around 400,000; and an estimated 5-10 million people are HIV-
positive 
1990 - Jonathan Mann resigns as WHO AIDS Program Director 
- Ryan White died and the Ryan White Care Act was proposed by US Congress 
- IAS made a statement that future International AIDS Conferences would not be held 
in countries where HIV-positive immigration is illegal 
- 307,000+ cases were reported to the WHO, where they estimated that the actual 
number should have been closer to 1 million, and an estimated 8-10 million PLWHA 
- There was an estimated 3 million women that were said to have given girth to 3 
million infants, estimating that 700,000 infants were likely to have been infected with 
HIV 
1991 - ddc (dideoxycytidine) was a treatment for HIV patients but became intolerant of AZT 
- MTCT was more viable than previously thought 
- The red ribbon became a symbol in support of PLWHA 
- There were 450,000 estimates of reported cases to the WHO worldwide, with 9-11 
million PLWHA, 5-7 million were men while 3-5 million were women 
1992 - WHO recommended that people at risk for HIV/AIDS should live in communities 
where condoms were both readily available and affordable 
- CDC changed the definition of AIDS to include blood cell counts 
- France researchers were brought to trial because of accusations of allowing for HIV to 
be contaminated in the blood supply 
- India‟s government allocated $100 million to the National AIDS Control Project for 
the next 5 years 
1993 - Resistant HIV forms to AZT was apparent and seemed to be transmissible 
- Romania had about 98,000 infected orphans 
- Russia started its large scale screening for HIV/AIDS, and the RIGA initiative was a 
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move from mass testing to voluntary testing 
- WHO recognized that AIDS could impact health and economic development but the 
WHO did not wand it to be the main agenda at meetings 
- US CDC changed the definition of AIDS to include: opportunistic infections and CD4 
cell counts below 200 
- Worldwide estimates were at 2.5 million cases 
1994 - Large movement toward HIV advertisements, especially in traveling places  
- Study found that MTCT was halved because of the use of C-Sections 
- Study ACTG076 found that AZT reduces MTCT by two-thirds  
- There were about 985,119 reported cases to the WHO 
1995 - By January 1 WHO estimated PLWHA: 18 million adults, 1.5 million children, and 
1,000,000 cases were reported to WHO 
- HIV/AIDS became leading cause of death in US for ages 25- to 44-year-olds 
- PLWHA Conference in Cape Town, South Africa was first African HIV Conference 
- South Africa Ministry of Health estimated that 850,000 people were HIV-positive in 
the country, accounting for 2.1% of the population and 8% of pregnant women 
- 7-8 million women pregnant in South Africa 
- The WHO spoke out about the inadequacy of the international HIV response  
1996 - US introduced and conducted home sampling testing 
- NVP was approved by the FDA as a reverse transcriptase inhibitor 
- Scientists said that AIDS could now be treated as a chronic disease with many 
medications, or combination therapy 
- The first White House AIDS strategy was created 
1997 - The number of AIDS deaths and the number of HIV-positive babies decreased 
- President Clinton set a 10-year target for the creation of the AIDS vaccine 
- NIH set up an HIV Research and Development center 
- United States Agency for International Development (USAID) said that 40 million 
children in developing nations would lose one or both parents to AIDS by 2010 
1998 - Glaxo Wellcome, drug company, cut price of AZT by 75% after it found that it could 
prevent MTCT in Thailand study 
- Another study found that AZT could reduce MTCT to less than 1% 
-  The first human trial of AIDSvax was conducted with 5,000 participants 
- UN new recommendations stated that women should decide how to feed their babies, 
but was seen as a push for formula feeding 
- South African AIDS activist, Gergu Dlamini was beaten 
- South African President, Mbeki, speaks out against HIV/AIDS silence and stigma 
1999 - Scientists found that chimpanzees (SIV) most likely introduced HIV to the human 
population through African chimpanzee hunters 
- HIV became the fourth leading cause of death in the world 
- In South Africa, myths emerged about having sex with a virgin to cure HIV 
- President Mbeki said that AZT was toxic and bad for people‟s health 
- South Africa battled with the US on ARV prices 
- Single dose NVP became affordable and effective in PMTCT in Uganda 
- UK offers all pregnant women HIV test to prevent MTCT 
- First time in history that more women than men were infected in Africa 
- UNAIDS estimated that 33 million PLWHA, 2.6 million died in 1999, which was 
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higher than any other year 
2000 - President Mbeki claimed that HIV was not the cause of AIDS 
- In April, Mbeki stated that African AIDS is different 
- Gates Foundation contributed $50 million for ART for HIV-positive pregnant women 
- President Clinton said HIV/AIDS is a threat to national security for some nations 
- Many African countries rejected an agreement for a loan from drug companies to 
purchase ARV therapies because the agreement would not help 
- Botswana found that 4 of every 10 pregnant women were HIV-positive 
- 5,000 scientists signed the Durban Declaration, stating that HIV caused AIDS 
- Nkosi Johnson, famous South Africa with HIV stated that the government should give 
AZT to all HIV-positive pregnant women  
2001 - ARV prices were off-set in South Africa because India and Brasil companies made 
their own generic forms, at a price of less than $1 per day 
- Kofi Annan, UN Secretary General, called for HIV/AIDS funds to increase tenfold in 
developing countries 
- 189 countries signed the Declaration of Commitment on HIV/AIDS 
- AIDS South Africa activists took legal action against the South African Ministry of 
Health for continuing to refuse ARVs to prevent MTCT 
- In December, the ruling was that South Africa gives out free NVP 
2002 - Colin Powell advocates for condoms while the Bush Administration does not 
- WHO published guidelines on ARV treatment in resource-poor settings 
- South Africa government promised to start giving nevirapine to HIV-positive 
pregnant women and pre-exposure prophylaxis to rape victims  
- South African Sesame Street introduced HIV-positive character, Kami 
- FDA approved first rapid test  
- Reports stated that women make up 58% PLWHA in Africa and 50% of all cases 
worldwide 
- USAID introduced ABC program (Abstinence, Be Faithful, Wear Condoms) 
2003 - US reports spending $15 billion in next 5 years for HIV/AIDS 
- Expert group stresses unsafe sex as the primary transmission mode in Africa 
- AIDSvax not work 
- South Africa – Treatment Action Campaign (TAC) filed manslaughter charges 
against the South African Ministry of Health, also stating that South Africa is 
responsible for 600 deaths per day 
- WHO declared a global public health emergency for failure to deliver treatment to 
nearly 6 million PLWHA in developing countries 
- South Africa approves free ARVs in public hospitals in November 
- WHO introduced 3 by 5 plan, that 3 million PLWHA would be on ARVs by 2005 
2004 - South Africa rolls out program to give free ARVs to PLWHA starting in 5 hospitals in 
the richest province, Gauteng 
- Bush Administration introduce PEPFAR to implement $15 billion  
- South Africa TAC activists nominated for Nobel Peace Prize, but did not win 
2005 - Nelson Mandela‟s oldest son died of AIDS 
- Publication of death certificates in South Africa found to be misreported between 
2000-2001, such that two-thirds of them were underestimates of HIV-related deaths 
- IOM published that NVP was safe and effective for PMTCT 
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- South Africa antenatal clinic survey found that 29.9% of pregnant women were HIV-
positive at the end of 2004 
- G8 Summit leaders promised to provide universal access to ARVs by 2010 
- South Africa Democratic Alliance published  
- 3 by 5 goal was not reached 
2006 - PEPFAR said that 401,000 people were on ARVs in 15 countries 
- UNAIDS 25 year anniversary report stated that HIV declined prevalence rates were 
found in Kenya, Burkina Faso, and Haiti 
- UNAIDS also reported increased funding figures from $300 million in 1996 to $8.3 
billion in 2005 
- 5th anniversary of UNGASS where a declaration was set on standards and goals to 
guide the world on the global response to HIV/AIDS 
- Vatican started thinking about changing its policy on condoms to prevent HIV 
infection but they still opposed condom use 
- US introduced the major medical contribution of 1 pill per day for HIV medication 
- XDR-TB prevalence rise in South Africa, all 25 patients were also HIV-positive 
- Launch of Product RED 
- Major findings from 2 NIH studies in Africa found that male circumcision greatly 
reduced HIV transmission by 50% 
2007 - International microbicide study shockingly did not help reduce HIV infection rates 
- Gambia President though to have had cure for HIV/AIDS but it was not true, but he 
also took people off combination ART 
- In June, the new South Africa Ministry of Health plan was to: 1- reduce new 
infections by 50%, and 2- bring treatment to more than 80% PLWHA 
- G8 Summit reduced original goal to: have approximately 5 million people getting 
access to ARVs over the next few years, which saw much criticism 
- In August, South Africa Deputy Minister of Health was fired  
- Botswana reduced HIV infection rates and MTCT to less than 4% 
- Hundreds of South Africans involved in AIDS vaccine might have increased their risk 
as a result of the study 
- President Mbeki still did not believe that HIV causes AIDS 
2008 - South African took scientists to court (Rath) for distributing and promoting vitamins 
as HIV remedies in unauthorized medical trials 
- PEPFAR was renewed and $48 billion was funded for years 2009-2013 
- UNAIDS said it would not make 2010 goals 
- President Mbeki resigns 
- Harvard study found that 330,000 lives were lost between 2000-2005 as a result of the 
South African government‟s failure to distribute ARVs 
- US approves needle exchanges again 
2009 - US travel ban lifted 
- Washington DC reported higher rates than West African countries 
- Catholic Pope made a statement that condoms increase risk for HIV 
- HIV-1 genome was mapped 
- UNAIDS and WHO stated that more PLWHA were receiving ARVs, a 36% increase 
from the previous year 
- Report stated that 45% of HIV-positive pregnant women were getting ARVs in Sub-
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Saharan Africa 
- UNAIDS report said that there by a decrease in HIV incidence by 17% in 2001 
2010 - Beginning January 4, PLWHA could travel and immigrate to the US 
- Because the US travel ban was lifted, IAS announced that Washington DC would be 
the site of the 2012 International AIDS Conference 
- South Africa epidemiology team stated that ARVs could be used as a treatment or 
PEP for HIV transmission 
- WHO PMTCT guidelines changed 
- WHO PLWHA guidelines also changed from CD4 count of less than 200 to CD4 
count of less than 350 
- Vienna International AIDS Conference theme was “Rights Here, Rights Now,” 
advocating a more human rights perspective toward HIV/AIDS response 
- Trial CAPRISA004 Microbicide study found effective 
- United Nations Children‟s Fund (UNICEF) and UNAIDS reported the largest number 
of people starting ARVs ever, at 5.25 million people on ART at the end of 2009 
- Catholic Pope promoted use of condoms to reduce HIV/AIDS transmission 
- Phase III PEP trial: iPEX found that this PEP could reduce transmission by 44% in 
the population of men who have sex with men 
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